Completed PHASE2 INTERVENTIONAL 1-arm NCT00251225

A Study of Imatinib and Docetaxel in Prostate Cancer

A Phase II Study of Imatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer

Sponsor: Leonard Appleman

Updated 9 times since 2017 Last updated: Jul 10, 2017 Started: Aug 31, 2005 Primary completion: Mar 31, 2009 Completion: Mar 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00251225, this PHASE2 trial focuses on Prostate Cancer and remains completed. Sponsored by Leonard Appleman, it has been updated 9 times since 2005, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2023 — Jul 2024 [monthly]

Completed PHASE2
Dec 2022 — Jan 2023 [monthly]

Completed PHASE2
Jan 2021 — Dec 2022 [monthly]

Completed PHASE2

▶ Show 4 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Sep 2017 — Jun 2018 [monthly]

Completed PHASE2
Feb 2017 — Sep 2017 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Aug 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Leonard Appleman
Novartis Pharmaceuticals

Data source: University of Pittsburgh

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Pittsburgh, United States